← Back to Search

AI and mechanic modeling for Genetic disorder

N/A
Waitlist Available
Led By Azadeh Nasrazadani, MD,PHD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Eligibility will be evaluated by the study team according to the following criteria. Subjects must meet all of the inclusion and none of the
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights

Summary

To assess for potential pitfalls and to assess the feasibility of the approach of analysis of new tumor biopsies for selection of standard of care treatment selection in patients with metastatic hormone receptor positive breast cancer who have developed disease progression on 1st line endocrine therapy combined with a CDK4/6 inhibitor.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average of 1 year. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and adverse events (AEs)

Trial Design

1Treatment groups
Experimental Treatment
Group I: AI and mechanic modelingExperimental Treatment1 Intervention
Participants with advanced/unresectable stage III or metastatic HR+ breast cancer with progression on a CDK4/6i and an AI will be eligible for study participation. The key action in this study will be the acquisition and analysis of tumor and blood for selection of standard of care systemic therapy. Tumor and blood will also be obtained at the time of disease progression to provide critical data for reverse translational model building. This will also provide insight into mechanisms of resistance for the administered standard of care therapy that can be used for future models to optimize selection of next-line therapy.

Find a Location

Who is running the clinical trial?

Phase One FoundationOTHER
4 Previous Clinical Trials
183 Total Patients Enrolled
M.D. Anderson Cancer CenterLead Sponsor
3,039 Previous Clinical Trials
1,799,655 Total Patients Enrolled
Azadeh Nasrazadani, MD,PHDPrincipal InvestigatorM.D. Anderson Cancer Center
~80 spots leftby Nov 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top